A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Veracyte, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 566,634 shares of VCYT stock, worth $21.2 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
566,634
Previous 566,634 -0.0%
Holding current value
$21.2 Million
Previous $12.3 Million -0.0%
% of portfolio
0.03%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$18.86 - $23.55 $10.7 Million - $13.3 Million
566,634 New
566,634 $12.3 Million
Q4 2023

Feb 14, 2024

SELL
$19.72 - $28.68 $7.83 Million - $11.4 Million
-397,287 Reduced 89.89%
44,700 $1.23 Million
Q3 2023

Nov 14, 2023

SELL
$22.33 - $29.92 $15.1 Million - $20.2 Million
-676,079 Reduced 60.47%
441,987 $9.87 Million
Q2 2023

Aug 14, 2023

BUY
$20.96 - $26.99 $23.4 Million - $30.2 Million
1,118,066 New
1,118,066 $28.5 Million
Q1 2023

May 15, 2023

SELL
$20.58 - $27.89 $4.65 Million - $6.3 Million
-225,815 Closed
0 $0
Q4 2022

Feb 14, 2023

BUY
$15.31 - $29.94 $776,599 - $1.52 Million
50,725 Added 28.97%
225,815 $5.36 Million
Q3 2022

Nov 14, 2022

BUY
$16.58 - $27.9 $2.9 Million - $4.89 Million
175,090 New
175,090 $2.91 Million
Q4 2021

Feb 14, 2022

SELL
$36.09 - $53.79 $6.67 Million - $9.94 Million
-184,705 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$35.62 - $52.97 $6.58 Million - $9.78 Million
184,705 New
184,705 $8.58 Million
Q3 2019

Nov 15, 2019

SELL
$23.87 - $30.93 $6.28 Million - $8.13 Million
-263,010 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$22.1 - $28.56 $334,815 - $432,684
-15,150 Reduced 5.45%
263,010 $7.5 Million
Q1 2019

May 15, 2019

BUY
$12.0 - $25.76 $3.34 Million - $7.17 Million
278,160 New
278,160 $6.96 Million

Others Institutions Holding VCYT

About VERACYTE, INC.


  • Ticker VCYT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,575,904
  • Market Cap $2.67B
  • Description
  • Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...
More about VCYT
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.